🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is a multicenter, non-randomized, single-dose, parallel-group study. E...
Status
Completed
Location
Progenics Pharmaceuticals, Inc.
Start Date
2004-03
Trial ID
NCT01367522
Treatments Being Tested
This study is a single-center, randomized, open-label, active and placebo-c...
Status
Completed
Location
Progenics Pharmaceuticals
Start Date
2006-03
Trial ID
NCT01367535
Treatments Being Tested
The purpose of this study is to describe the effects of methylnaltrexone in...
Status
Completed
Location
Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald
Start Date
2010-01
Trial ID
NCT01596777
This is an open-label, Phase I study. Study treatments will entail a four-w...
Status
Completed
Location
Progenics Pharmaceuticals, Inc.
Start Date
2002-06
Trial ID
NCT01367496
To test the effectiveness of MNTX in advanced illness subjects....
Status
Completed
Location
Progenics Pharmaceuticals, Inc.
Start Date
2003-02
Trial ID
NCT00401362
Treatments Being Tested
This study is evaluating the Pharmacokinetics of MNTX in healthy control su...
Status
Completed
Location
Progenics Pharmaceuticals, Inc.
Start Date
2004-03
Trial ID
NCT01367509
Treatments Being Tested
To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks...
Status
Recruiting
Location
MD Anderson Cancer Center
Start Date
2024-01-10
Trial ID
NCT06162377
Treatments Being Tested
This is a 3 month open-label extension study that allows patients who compl...
Status
Completed
Location
Progenics Pharmaceuticals, Inc.
Start Date
2004-03
Trial ID
NCT01367613
Treatments Being Tested
The purpose of this study is to examine the safety and activity of MNTX in ...
Status
Completed
Location
Progenics Pharmaceuticals, Inc
Start Date
2007-10-19
Trial ID
NCT00640146
Treatments Being Tested